Rebuttal and response to: "The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?" by Ahmet Emre Eskazan, Muhlis Cem Ar and Teoman Soysal.


Sorry, we couldn't extract an abstract for this paper.
DOI: 10.3109/10428194.2014.947757


  • Presentations referencing similar topics